Promising Clinical Trial Results Position NextCure’s NC410 as a Potential Game-Changer in Cancer Treatment

NextCure (NXTC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $8.00 price target.

Emily Bodnar’s rating is based on a compelling combination of clinical trial results and the potential impact on standard of care for certain cancer treatments. NextCure’s NC410, when combined with pembrolizumab (pembro), has shown promising initial results in a Phase 1b study, particularly in microsatellite stable colorectal cancer (MSS-CRC) and ovarian cancer cohorts. The data exhibited not only a notable overall response rate (ORR) but also a disease control rate (DCR) that surpasses current standards of care. Furthermore, the median progression-free survival (PFS) observed was significantly longer than what is typically expected with standard treatments, hinting at the drug’s potential to alter the disease course for patients with dismal prognoses.

Furthermore, Bodnar is encouraged by the fact that additional data on NC410’s efficacy and durability of response is expected to be presented at the upcoming ASCO meeting. The inclusion of 20 more MSS-CRC patients in the forthcoming update is seen as an opportunity to validate the initial findings and to better understand the drug’s impact in a larger patient pool. The anticipation of consistent ORR and possibly extended PFS in a larger cohort strengthens the belief that NC410 could meaningfully compete with or improve upon existing standards of care. This, coupled with the drug’s advancement towards an Investigational New Drug (IND) submission and the initiation of GLP toxicology studies, underpins the positive outlook and the Buy rating assigned by Bodnar.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

NextCure (NXTC) Company Description:

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.